Aemetis, Inc. (NASDAQ:AMTX) Sees Large Increase in Short Interest

Aemetis, Inc. (NASDAQ:AMTX - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 5,320,000 shares, an increase of 14.7% from the March 15th total of 4,640,000 shares. Based on an average daily volume of 1,220,000 shares, the short-interest ratio is presently 4.4 days.

Hedge Funds Weigh In On Aemetis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMTX. JPMorgan Chase & Co. raised its stake in shares of Aemetis by 16.0% in the 1st quarter. JPMorgan Chase & Co. now owns 16,362 shares of the specialty chemicals company's stock worth $208,000 after buying an additional 2,256 shares in the last quarter. Raymond James & Associates lifted its holdings in Aemetis by 64.4% in the 1st quarter. Raymond James & Associates now owns 18,120 shares of the specialty chemicals company's stock valued at $230,000 after acquiring an additional 7,097 shares during the last quarter. Citigroup Inc. boosted its position in shares of Aemetis by 15.0% during the 1st quarter. Citigroup Inc. now owns 50,504 shares of the specialty chemicals company's stock valued at $640,000 after purchasing an additional 6,603 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Aemetis by 57.0% in the 1st quarter. MetLife Investment Management LLC now owns 15,153 shares of the specialty chemicals company's stock worth $192,000 after purchasing an additional 5,501 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Aemetis by 26.6% in the 1st quarter. Rhumbline Advisers now owns 36,936 shares of the specialty chemicals company's stock worth $468,000 after purchasing an additional 7,759 shares in the last quarter. 27.02% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on AMTX. Truist Financial dropped their price objective on shares of Aemetis from $5.00 to $3.50 and set a "hold" rating on the stock in a research note on Tuesday, January 23rd. Stifel Nicolaus dropped their price target on Aemetis from $8.00 to $6.50 and set a "buy" rating on the stock in a research report on Wednesday, February 21st.

Aemetis Stock Down 4.0 %

NASDAQ AMTX traded down $0.18 on Friday, hitting $4.29. The stock had a trading volume of 468,486 shares, compared to its average volume of 2,907,940. The company's 50-day moving average is $4.07 and its two-hundred day moving average is $4.34. The stock has a market cap of $182.80 million, a price-to-earnings ratio of -3.25 and a beta of 1.01. Aemetis has a one year low of $1.16 and a one year high of $8.99.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its earnings results on Thursday, March 7th. The specialty chemicals company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.01. The business had revenue of $70.76 million for the quarter, compared to the consensus estimate of $80.08 million. During the same period in the previous year, the firm earned ($0.63) EPS. On average, sell-side analysts anticipate that Aemetis will post -1.44 earnings per share for the current year.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.